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Introduction
Cardiovascular disease (CVD) is the main cause of death in 
persons with diabetes worldwide.1,2 In 2010, peripheral arte-
rial disease (PAD) was estimated to affect more than 200 
million people globally, and approximately 20% over the age 
of 60 years in the United Kingdom.3,4 PAD is considered to 
be one of the most prevalent of morbid diseases5 with the 
associated disability and mortality increasing in the last two 
decades, more so in women than men, and no longer 
restricted to the elderly population and thereby representing 
a major public health challenge worldwide.6
Intermittent claudication is the commonest complaint in 
symptomatic PAD, but non-invasive vascular assessments 
such as ankle brachial index (ABI) reveal asymptomatic PAD 
to be several times more common.7,8 Delaying the diagnosis 
of PAD can potentially lead to the need for revascularisation 
and lower extremity amputation (LEA) associated with an 
increased risk of myocardial infarction (MI), stroke and early 
mortality.9 Diagnosis of PAD at the asymptomatic stage will 
therefore facilitate interventions to modify known risk 
factors.7
Diabetes is one of the main causes of non-traumatic LEA 
due to micro and macro-vascular complications such as 
peripheral neuropathy (DPN) and/or PAD. Co-existing micro-
vascular disease (MVD) such as diabetes-related retinopathy 
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Objectives: Peripheral artery disease is a major cardiovascular disease affecting more than 200 million people globally and 
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and nephropathy increases the amputation risk, by more than 
20 times10,11 and death following amputation.12
In 2019, there were an estimated 463 million people with 
diabetes globally which is anticipated to increase to 700 mil-
lion by 2045.13,14 The International Diabetes Federation 
(IDF) has stated that every 30 seconds a lower limb or part of 
a lower limb is lost to amputation somewhere in the world as 
a consequence of diabetes which amounts to as many as 20 
per day in the United Kingdom.13,15 Approximately 55% of 
those with diabetes, who have undergone an LEA, will 
require amputation of the contralateral limb within 2–3 years 
with an increased mortality rate of up to 77% within 5 years.16 
A delayed diagnosis can lead to critical limb ischaemia (CLI) 
which has a very poor prognosis with the mortality rate at 
15%–30% within 1 month increasing to 50% at 1 year and 
reaching 74% after 5 years17 which is higher than breast can-
cer, colon cancer, and prostate cancer.18 Good diabetes con-
trol, including improvement in diet, increased activity levels 
and eliminating unhealthy behaviours (e.g. excessive alco-
hol, smoking and unhealthy sleep patterns) along with medi-
cation adherence can however contribute to delaying the 
onset or progression of diabetes-related complications such 
as peripheral neuropathy and peripheral arterial disease.19,20
NICE recommends foot examination for persons with 
diabetes as part of their annual review.21 NICE and several 
other guidelines recommend ankle brachial pressure index 
(ABI) as the preferred non-invasive method for detecting 
PAD and the 10-g monofilament for detecting impaired 
peripheral sensory neuropathy, in primary and community 
care settings.22–24 However, inconsistencies in diabetic foot 
screening guidelines exist between regional, national and 
international recommendations which contributes to ine-
qualities of care.25
The recommended use of ABI for PAD diagnosis is not 
however without its limitations as highlighted in a recent 
guideline update by NICE.21 The presence of distal periph-
eral neuropathy, medial arteriosclerosis and incompressible 
arteries particularly affect the performance of ABI.26–28 The 
recognised limitations of ABI in the diabetic population, 
therefore, suggests that other methods for detecting PAD 
should be explored.
Pulse volume waveform (PVW) is usually used to locate 
arterial lesions and is especially useful in the setting of calci-
fied vessels as it does not require the vessel to be occluded, 
as needed to perform an ABI, and therefore results are not 
influenced by the presence of arteriosclerosis.29 PVW analy-
sis carried out at ankle level provides a qualitative assess-
ment of peripheral arterial blood flow.
In an attempt to combat the rising number of diabetes-
related LEAs, integrating foot checks into established diabetic 
eye screening programmes could therefore be a viable option. 
Diabetic retinopathy screening (DRS) programmes have con-
tributed to relegating diabetes-related retinopathy from being 
the leading cause of certifiable blindness among working age 
adults in England and Wales,30 and in a retrospective analysis 
of newly recorded certifications of visual impairment in Wales 
during 2007–2015, sight loss was reduced by almost 50%.31 It 
is well recognised that the success of any screening interven-
tion is dependent on the early detection of complications and 
timely referral for treatment.32 In the context of PAD if not 
picked up early, disease will progress to non-healing ulcera-
tions which often necessitate challenging distal revascularisa-
tion or angioplasty to improve distal blood flow.33
In the recent Fourth National Diabetes Foot-care Audit 
(2019), it was reported that 2.7% of people with diabetes 
presenting with severe foot ulceration underwent major 
amputation within 6 months, with 14% dying within 1 year.34
Methods
This cross-sectional feasibility study aimed to explore the 
acceptability of targeted screening for PAD and peripheral 
sensory neuropathy on the same occasion as diabetes 
retinopathy screening. This study was conducted over an 
8-week period during 2017 at two hospital sites in Wales 
(University Hospital of Wales and Royal Glamorgan 
Hospital) where diabetic retinopathy screening was being 
carried out.
Ethical approval was granted by both the Chelsea 
Research Ethics Committee, London and Cardiff 
Metropolitan University Ethics Committee, Cardiff.
Persons with diabetes registered on the Diabetic Eye 
Screening Service Wales (DESW), Optimize database, due 
for eye screening appointments at the two designated hospi-
tal sites in Wales during the recruitment period were sent the 
study information and invitation letter offering foot screen-
ing at their forthcoming eye screening appointment. For 
inclusion into the study, participants had to be at least 
18 years of age and able to give informed consent, be trans-
ferrable to a patient couch, lie supine for up to 10 min and 
have at least one lower limb.
The DESW Healthcare Assistants identified partici-
pants fulfilling the inclusion criteria. Following the assess-
ment of visual acuity and the administration of Tropicamide 
eye drops, those agreeing to take part were then escorted 
by the Podiatry Assistant to an adjacent room for their foot 
checks. For the arterial assessment, measuring ABI and 
PVW, required the participant to lay supine with the dual 
chamber blood pressure cuffs from an automated device 
(Dopplex Ability, Huntleigh Healthcare), attached to all 
four limbs. The participant remained supine, motionless 
and not allowed to talk or smoke for the duration of the test 
of approximately 3–5 min. All mobile phones were 
required to be at least 1 metre away from the device. 
Systolic blood pressures and PVW of each limb were 
measured automatically and simultaneously, negating the 
need to rest the participant between measurements. The 
device automatically calculated the ABI (the highest ankle 
pressure divided by the highest brachial pressure for each 
lower limb) and visually displayed the PVW profile. ABI 
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measurements were classified as normal (0.9–1.30), mild 
obstruction (0.7–0.89), moderate obstruction (0.4–0.69), 
severe obstruction (<0.4) or poorly compressible 
(>1.30).35
The Rumwell and McPharlin36 grading system was used 
to grade the PVW profiles as normal (Grade A), mild obstruc-
tion (Grade B), moderate obstruction (Grade C) and severe 
obstruction (Grade D) (Figure 1).
Light touch peripheral sensory neuropathy was assessed 
using the 10-g monofilament21 at five plantar load bearing 
sites on each foot. Following the foot screening, the partici-
pant was accompanied back to the original room where reti-
nal photography was conducted. All results were stored on 
computer software for scrutiny and analysis.
The results of the retinal images were sent to the Diabetic 
Eye Screening Wales central grading centre with the foot 
screening results being sent to the chief investigator (JL). 
Onward referrals were according to the locally agreed path-
ways. GPs received copies of both eye and foot screening 
reports. Randomly selected participants (n = 100) took part in 
a short telephone questionnaire, exploring their combined 
screening experience.
Statistical analysis
Contingency tables were analysed using Pearson’s chi-square 
test and continuous variables were tested for normality using 
the Kolmogorov–Smirnov test. Normally distributed data are 
presented as mean values plus standard deviation (SD) and 
comparisons made with the independent-samples t-test. Data 
not normally distributed are presented as median values and 
interquartile ranges (IQR), and non-parametric analyses per-
formed using the Mann–Whitney U test. All comparisons 
were two-sided and correlation analysis undertaken using 
Pearson’s method. Binary logistic regression was used to iden-
tify predictors of PAD, with variance inflation used to confirm 
the absence of multi-collinearity between individuals and this 
was confirmed by goodness of fit determined using Pearson’s 
and Hosmer–Lemeshow’s test. Statistical significance was 
deemed present with a p < 0.05. Statistical analyses were per-
formed with the IBM SPSS Statistics software version 22.0 
(IBM Corp., Armonk, NY and Minitab® version19).
Results
Of the 484 individuals invited for diabetic retinopathy screen-
ing, 13 cancelled their appointment and a further 74 did not 
attend. Of the 397 that did attend, 33 did not meet the study’s 
inclusion criteria and of 43 who did not take part, 31 declined, 
8 had time constraints and 4 had family member awaiting in 
a car. Finally, of the 364 individuals invited, 321 (88%) par-
ticipated in the combined screening service (Table 1).
The mean age of the study cohort was 64 years, 56% were 
males, 7% were current smokers with 53% considering 
themselves to be non-smokers and 40% were ex-smokers 
(Table 2).
Figure 1. Pulse volume waveform grading system (Rumwell and McPharlin).36
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Table 1. Participant recruitment flow diagram.
Appointments sent (n=484)
Excluded (n=87)
 Did not attend (n=74)
 Cancelled (n=13)
PAD (one or both limbs)
 With PAD (n=86, 
26.4%) 
Included in study (n=321)
Excluded from study (n=76)
 Not meeting inclusion criteria (n= 33)
 Declined to participate (n=43)
(31=declined; 8= time constraints; 
4=family waiting in car)
Neuropathy (one or both limbs)







PAD & neuropathy (one or 
both limbs)
•  With both (n= 4, 1%)
PAD: peripheral artery disease.
Whereas 64% were known to have hypertension, other 
vascular complications, that is, coronary heart disease 
(CHD), stroke, and previous PAD were recorded in only 
10% or less of the participants. There were 3% with impaired 
peripheral sensory neuropathy with two or more sites insen-
sate using the 10 g monofilament, in one or both feet.
In this study, those with an ABI < 0.9 and/or PVW 
Grades B, C or D were considered as having PAD. About 
26.4% (n = 86) were found to have previously undetected, 
asymptomatic PAD as self-reported by the participants 
(Figure 2(a)–(c)).
Binary Logistical regression was used to explore for the 
potential risk factors for PAD. Of the variables investigated 
in this study, the following predictors were found to be sig-
nificantly associated with the presence of PAD, age, coro-
nary heart disease, gender and ABI (Table 3).
The combined adjusted R2 value of 17.2% confirms that 
this is a predictive model of PAD. The model was also 
adjusted for the effect of age as it could be argued that the 
effect of all the variables was due to age. ABI, gender and 
CHD remained significant even when the age of the sample 
was adjusted for. The analysis of variance confirms that this 
is highly significant both combined (p < 0.001) and individ-
ually (Table 4).
Interestingly, body mass index (BMI) was not found to be 
significantly related to PAD in this group, neither was smok-
ing habits. When considering differences between those with 
PAD and those without, age, gender, CHD and previous vas-
cular intervention were the only variables to show a statisti-
cally significant difference between the two groups.
Although specific data were not collected regarding dia-
betes complications due to lack of GP engagement, a large 
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proportion of participants (between 70–80%) were ‘una-
ware’ of the impact that diabetes can have on the circulation 
to the lower limb and feet, and therefore, did not recognise 
the importance of regular foot checks, thereby increasing the 
risk of ulceration and potential amputation. After the com-
pletion of the study, a random selection of participants 
(n = 100) were contacted by telephone and asked about their 
combined screening experience. All of those contacted said 
they would welcome the addition of foot screening to the eye 
screening service in the future.
Discussion
Diabetic foot disease is one of the most devastating 
chronic complications of diabetes worldwide with widely 
different amputation rates, due to variations in foot care to 
include examination procedures and frequency and the 
inadequate detection and modulation of cardio-metabolic 
risk factors. Screening for PAD in studies involving the 
general population without cardiovascular risk has proven 
to be unyielding.37 However, in this novel, targeted feasi-
bility study in people undergoing screening for diabetes-
related retinopathy, determining both ABI and PVW, and 
assessing peripheral neuropathy we revealed that almost a 
third of the participants had previously undiagnosed PAD 
with a much small proportion (3%), having DPN. The 
mean age of those with PAD were a decade older than 
those without; however, similarly to Sampson,6 this study 
also highlighted that more females than males were found 
to have PAD.
Although the non-invasive assessment of ABI and pulse 
volume waveforms (PVW) are well recognised and recom-
mended means of identifying asymptomatic PAD, they are 
predominantly utilised in secondary care. PVW has been 
shown to be more reliable than ABI in the diabetic popula-
tion, being uninfluenced by the presence of arteriosclerosis38 
and ABI is also considered less reliable in those with lower 
levels of disease.27,38 However, in this study, a device com-
bining ABI with PVW was used allowing both results to be 
ascertained simultaneously. The use of PVW in this study 
also supports NICE recommendations for research into other 
modalities for identifying PAD, other than ABI, in this high-
risk population.39
Those reporting CHD were also found to have asympto-
matic PAD. Treating PAD in its asymptomatic stage is 
highly beneficial, particularly with respect to mitigating 
common risk factors of atherosclerotic disease in the dif-
ferent vascular beds7 with long-term health care cost 
benefits.40
Feedback from both participants and staff confirmed that 
they would welcome a combined foot and eye screening ser-
vice, thereby limiting the number of outpatient sessions, a 
strategy which has also been suggested by others32 with the 
potential to also reduce cardiovascular disease and prema-
ture mortality in this vulnerable high-risk population.
It is not only important for all health professionals to be 
more astute in identifying PAD to ensure timely manage-
ment of associated risk factors but there is also a real need to 
further increase awareness of PAD especially in people with 
diabetes. A public education programme by the Peripheral 
Table 2. Demographic characteristics of the PAD and non-PAD groups.












between PAD and 
no PAD groups
(p value)









 Current 23 (7) 5 (23) 18 (78)  
 Previous 128 () 23 (18) 105 (82) NS
 Non 170 (53) 57 (34) 113 (66)  
Hypertension 206 (64) 70 (34) 136 (66) NS
Dyslipidaemia 210 (7) 69 (33) 141 (67) NS
Stroke 31 (10) 31 (100) 0 (0) NS
CHD 61 (3) 61 (100) 0 (0) < 0.005
Previous PAD 23 (7) 3 (13) 20 (87) NS
Previous DVT 9 (3) 1 (11) 8 (89) NS
Neuropathy 10 (3) 3 (30) 7 (70) NS
Previous vascular intervention 36 (11) 2 (6) 34 (94) < 0.005
BMI (mean/SD) 31.61 / 6.14 31.44 / 6.36 31.74 / 6.12 NS
Waist circumference (cm) (mean/SD) 104.63 / 13.24 106.4 / 16.7 104.1 / 13.9 NS
PAD: peripheral artery disease; DVT: deep vein thrombosis; SD: standard deviation; NS: nonsignificant; CHD: coronary heart disease; BMI: body mass index.
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Arterial Disease Coalition for the early detection and preven-
tion of PAD, but also to improve the quality of life of people 
with PAD,41 developed for both health care professionals and 
the public could be adopted and incorporated into diabetes 
education.
This feasibility study confirms the acceptability, to both 
the people with diabetes and health care professionals, of 
introducing a foot care assessment element on the same 
occasion as diabetic retinopathy screening.
Limitations
This feasibility study was limited in its scope, due to the 
absence of data from the diabetic screening service and 
primary care, to relate the foot examination findings with the 
retinopathy status and associated risk factors.
Health economic evaluation was not intended at this 
stage.
Conclusion
Screening for diabetes-related retinopathy and PAD has the 
ability to detect early disease which can facilitate timely inter-
ventions to reduce the risk of vision loss, lower limb and car-
diovascular disease, premature death and reduce health care 
costs while also improving quality of life. This study demon-
strated that combining foot and eye screening service is feasi-
ble and was well received by participants and staff alike, who 
Figure 2. Example of (a) both limbs normal ABI/Grade A PVW, (b) both limbs moderate ABPI/Grade B PVW and (c) left limb normal 
ABI/Grade A PVW, and right limb severe obstruction ABI/severe obstruction Grade D PVW.
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expressed a wish to see such a service being routinely pro-
vided in the future. Combined screening for diabetes-related 
complications would empower the people with diabetes by 
increasing their knowledge and awareness of the existence 
and importance of co-morbidities such as diabetes-related 
retinopathy, cardiovascular disease, diabetic neuropathy and 
nephropathy.
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